Dr. Beatrice Setnik Makes Waves!
Altasciences’ Chief Scientific Officer Selected as a PharmaVoice 100 Honoree
Dr. Beatrice Setnik, Chief Scientific Officer at Altasciences, has been named a 2024 PharmaVoice 100 honoree. Known as a dedicated and hands-on leader, Dr. Setnik has nearly 20 years of experience in clinical drug development, and was selected by the PharmaVoice team from nominations submitted by industry peers.
"Thank you very much to PharmaVoice for this honor, which would have been impossible without the support of my colleagues, the clients at Altasciences, and of course, my peers and collaborators over the years,” said Dr. Setnik. “To be included in a list of such incredible innovators and trailblazers is extremely humbling."
You may also be interested in these resources from Dr. Setnik
- Scientific Poster: Development of the Subject-Rated Comprehensive Drug Withdrawal Scale (CDWS) to Evaluate the Physical Dependence Potential of Investigational Drugs
- Webinar: CNS-Active Compounds–The Importance of Cognitive and Pharmacodynamic Testing During First-in-Human Trials
- Webinar: Demystifying the Conduct of Clinical Trials in Canada
- Podcast: The Many Faces of Recreational Drug Use—Episode 1
- Interview: Dr. Beatrice Setnik: Boldly Navigating the Future of Drug Development-Insights Care
- Feature: Medicine Maker’s Power List 2024